<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272764</url>
  </required_header>
  <id_info>
    <org_study_id>ALK5461-214</org_study_id>
    <nct_id>NCT02272764</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study of the Effects of Itraconazole on the Pharmacokinetics of ALKS 5461 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the impact of Itraconazole on the pharmacokinetics of ALKS 5461.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug-Drug Interaction - AUC0-t</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Area under the concentration time curve from time zero to the last measureable time point (AUC0-t) of ALKS 5461 in the presence and absence of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug-Drug Interaction - AUC0-inf</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Area under the concentration time curve from time zero to infinity (AUC0-inf) of ALKS 5461 in the presence and absence of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug-Drug Interaction - Cmax</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Maximum plasma concentration (Cmax) of ALKS 5461 in the presence and absence of itraconazole</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability will be measured by incidence of adverse events</measure>
    <time_frame>Up to 32 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Itraconazole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Itraconazole or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 5461</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALKS 5461 or placebo Sublingual tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Administered orally in a crossover design</description>
    <arm_group_label>Itraconazole</arm_group_label>
    <other_name>Itraconazole or placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 5461</intervention_name>
    <description>Administered sublingually in a crossover design</description>
    <arm_group_label>ALKS 5461</arm_group_label>
    <other_name>ALKS 5461 or placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a body mass index (BMI) of 18.0 - 30.0 kg/m2

          -  Is in good physical health

          -  Agrees to use an approved method of contraception for the duration of the study

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Has current evidence, or history of any clinically significant medical or psychiatric
             condition or observed abnormality

          -  Is currently pregnant or breastfeeding

          -  Has a history of or current infection with hepatitis B virus, hepatitis C virus, or
             human immunodeficiency virus (HIV)

          -  Has a lifetime history of opioid abuse or dependence

          -  Has current abuse or dependence on alcohol or any drugs

          -  Has used nicotine within 90 days prior to randomization

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjeev Pathak, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

